Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

Published:2017-03 Issue:3 Volume:18 Page:371-383
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zhang Pin,Sun Tao,Zhang Qingyuan,Yuan Zhongyu,Jiang Zefei,Wang Xiao Jia,Cui Shude,Teng Yuee,Hu Xi-Chun,Yang Junlan,Pan Hongming,Tong Zhongsheng,Li Huiping,Yao Qiang,Wang Yongsheng,Yin Yongmei,Sun Ping,Zheng Hong,Cheng Jing,Lu Jinsong,Zhang Baochun,Geng Cuizhi,Liu Jian,Peng Roujun,Yan Min,Zhang Shaohua,Huang Jian,Tang Li,Qiu Rongguo,Xu Binghe

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

2. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014

3. Treatment of metastatic breast cancer;Roché;Ann Oncol,2011

4. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer;Twelves;Crit Rev Oncol Hematol,2016

5. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone;Rivera;Breast Cancer Res,2010

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer;Frontiers in Pharmacology;2024-07-11

2. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

3. A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature;Medicine;2023-12-01

4. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study;Surgery Open Science;2023-12

5. Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801);Cancer Pathogenesis and Therapy;2023-10